The World Medical Association’s Declaration of Helsinki was revised on October 19, 2024, at the WMA’s 75th General Assembly — fittingly held in Helsinki again, sixty years after the original 1964 text. This is the tenth time the Declaration has been amended, and the first revision since 2013. For research administrators, IRB/ethics-committee staff, and sponsors, the practical question isn’t “what is the Declaration of Helsinki” (see CASRAI’s Declaration of Helsinki entry for that) — it’s what does the 2024 text now require that the 2013 text didn’t clearly say, and what does that mean for a protocol going in front of an ethics committee, or a consent form going in front of a participant, today.
Last verified 2026-08-16 against the current primary text at wma.net.
What changed in 2024 — at a glance
| 2024 provision | What it requires | Action item for protocols/consent |
|---|---|---|
| Environmental sustainability (§11) | Research must be “designed and conducted in a manner that avoids or minimizes harm to the environment and strives for environmental sustainability” — a topic with no precedent in earlier Declaration text. | Protocols should note steps taken to reduce environmental impact (materials, shipping, waste) where relevant; ethics committees can now legitimately ask about this. |
| Vulnerability reframed (§19–20) | Vulnerability is described as arising from “fixed or contextual and dynamic” factors, not a fixed list of “vulnerable populations.” Exclusion itself is named as a potential harm. | Protocols should justify inclusion/exclusion criteria against both the harms of inclusion and the harms of exclusion, not just cite a group’s label. |
| Meaningful community engagement (§6) | Engagement with participants and their communities “should occur before, during, and following medical research,” including participation in design and dissemination. | Protocols for community-based or population-specific research should describe engagement activities across the full lifecycle, not only at recruitment. |
| Post-trial provisions arranged in advance (§34) | Sponsors and researchers must arrange post-trial access to a beneficial intervention “in advance of” the trial, not describe it as an afterthought; specific information must be disclosed as part of informed consent. | Consent forms need a specific post-trial-access disclosure, not a general reference to “future availability.” |
| Underrepresented groups (§13) | “Groups that are underrepresented in medical research should be provided appropriate access to participation” — an affirmative access provision, not only a non-exclusion rule. | Recruitment plans should show active steps to include historically underrepresented groups where scientifically appropriate, not just an absence of exclusion criteria. |
| Obligations extend past physicians (§2) | The WMA states these principles “should be upheld by all individuals, teams, and organizations involved in medical research,” not physicians alone. | Multidisciplinary study teams (statisticians, coordinators, non-physician PIs) should be named as bound by the Declaration in SOPs, not just the physician-investigator. |
| Avoiding research waste (§21) | Research must be designed to “produce reliable, valid, and valuable knowledge and avoid research waste,” alongside the pre-existing requirement for scientific soundness. | Protocol justification sections should address why the study is needed (e.g., not duplicative of adequately powered existing evidence). |
| Data/biobank secondary use (§32) | Consent for “collection, processing, storage, and foreseeable secondary use” of data/biospecimens is now explicitly tied to the WMA Declaration of Taipei’s governance principles for health databases and biobanks. | Biobank and secondary-use consent language should reference governance obligations consistent with the Declaration of Taipei, not just a generic future-use clause. |
Table built directly from the current WMA primary text (wma.net/policies-post/wma-declaration-of-helsinki/), paragraph numbers as published. Directional framing of what shifted from the 2013 to 2024 text reflects the WMA’s own characterization of the revision (strengthened protections for vulnerable populations, improved clinical-trial transparency, reinforced fairness and equity) plus provisions, like §11’s environmental-sustainability language, that are new subject matter with no equivalent in prior Declaration text.
Why this revision happened
The 2024 text followed a roughly 30-month review process involving representatives from 19 countries and was adopted unanimously by the General Assembly. It is the Declaration’s tenth amendment since 1964 and its first since the 2013 Fortaleza revision. As with every revision since 2000, the changes add specificity rather than alter the document’s core commitments: physician (and now, more broadly, researcher) primacy of participant welfare over the interests of science and society remains the Declaration’s organizing principle.
What a protocol needs to address under the 2024 text
None of this replaces your institution’s or sponsor’s SOP template, but a protocol reviewed against the current Declaration should be able to answer each of the following without the reviewer having to infer it:
- Ethics committee review before enrollment begins (§23) — including, for international collaborative research, approval from ethics committees in both sponsoring and host countries.
- A documented risk/burden assessment (§16–18) that is continuously monitored and updated, not a one-time submission-stage exercise.
- An explicit statement of how inclusion/exclusion criteria were decided for any participant group in a situation of particular vulnerability (§19–20), weighing exclusion harms against inclusion harms.
- Post-trial provisions arranged before the trial starts (§34), for any intervention that could be identified as beneficial and reasonably safe — or an ethics-committee-approved exception if none are arranged.
- Public registration before the first participant is recruited (§35).
- A funding, affiliation, and conflict-of-interest disclosure that will also need to appear at publication (§36).
- Environmental-impact consideration where materially relevant to study design (§11) — this is new enough that many existing protocol templates simply don’t have a field for it yet.
What a consent form needs to address under the 2024 text
- Aims, methods, anticipated benefits, potential risks and burdens, researcher qualifications, funding sources, and any conflicts of interest, in plain language (§26).
- An explicit statement of the right to refuse or withdraw at any time without reprisal, and confirmation that refusal or withdrawal will not adversely affect the participant’s clinical care (§26, §31).
- The option for participants to be informed of the general outcome and results of the research (§26) — a participant-facing results-disclosure option that is easy to omit from boilerplate consent language.
- Where applicable, specific information about post-trial provisions (§34) — not a cross-reference to the protocol, but content disclosed directly to the participant.
- Where biospecimens or data will be retained for future/secondary use, consent framed around the Declaration of Taipei’s data-governance principles (§32), covering collection, processing, storage, and foreseeable secondary use separately from consent to the primary study procedures.
- For participants unable to give free and informed consent, documentation of assent where the participant is able to give it in addition to the legally authorized representative’s consent, with the participant’s dissent respected even if the representative has consented (§29).
Is the Declaration of Helsinki legally binding?
No — and the 2024 revision didn’t change that. The Declaration remains a WMA policy statement, not law; its authority comes from voluntary adoption by journals, ethics committees, sponsors, and national medical associations, and from its role as the explicit ethical foundation cited in ICH Good Clinical Practice (ICH E6), and from its own informed consent requirements mirrored in GCP. In the United States, it sits alongside, rather than replaces, the Common Rule (45 CFR 46) and Belmont Report framework and IRB review requirements. A U.S. multi-site trial is typically expected to satisfy all of these at once, not choose among them. See CASRAI’s Declaration of Helsinki dictionary entry for the full history, structure, and relationship to the Nuremberg Code.
Practical transition notes for sponsors and research offices
- Cite the version, not just the document. Protocol templates and publication statements that say a study “was conducted in accordance with the Declaration of Helsinki” should now specify the 2024 revision where the study was designed or amended after October 2024, since journals and ethics committees increasingly expect version-specific citation given the document’s revision history.
- Ongoing studies approved under the 2013 text are not automatically out of compliance. The Declaration itself has no retroactive enforcement mechanism; whether an active protocol needs a formal amendment to align with 2024 language is a decision for the reviewing ethics committee, not something the Declaration mandates on its own.
- Template gaps to check first: post-trial-provisions language, plain-language consent for secondary data/biospecimen use, and environmental-impact considerations are the three areas most likely to be genuinely absent from a template last updated for the 2013 text.
- Watch for ICH E6(R3) alignment. Because ICH E6 states its ethical principles “originate in the Declaration of Helsinki,” expect regulatory guidance and CRO/sponsor SOPs to reference the 2024 text as ICH E6(R3) implementation continues.
Frequently Asked Questions
When did the 2024 revision of the Declaration of Helsinki take effect?
The WMA adopted the revised text on October 19, 2024, at its 75th General Assembly in Helsinki, Finland. Unlike a regulation, it has no statutory “effective date” that triggers automatic compliance deadlines — adoption by ethics committees, sponsors, and journals happens on each organization’s own timeline.
What is genuinely new in the 2024 text rather than just reworded?
The environmental-sustainability provision (§11) is the clearest example of subject matter with no precedent in earlier versions of the Declaration. The reframing of vulnerability as “fixed or contextual and dynamic” rather than a list of named vulnerable groups, and the requirement that post-trial provisions be arranged in advance of the trial rather than merely described, are both meaningful strengthenings of existing 2013 concepts rather than entirely new topics.
Does the 2024 revision change how placebo controls are justified?
The substantive placebo-control test in §33 — permissible only where no proven intervention exists, or where compelling and scientifically sound methodological reasons justify it, and only where participants face no additional risk of serious or irreversible harm — is carried forward. See CASRAI’s clinical equipoise and placebo-controlled study design entries for how this constraint shapes trial design in practice.
Does the Declaration of Helsinki apply outside clinical trials?
Yes. It covers “medical research involving human participants, including research using identifiable human material or data” generally — not only interventional clinical trials. See CASRAI’s guide to clinical study design types for how different designs each need to satisfy its principles.
Who has to comply with the Declaration of Helsinki?
The WMA states its principles apply to “all individuals, teams, and organizations involved in medical research,” not physicians alone — a broadening made explicit in the 2024 text’s Preamble (§2). In practice, compliance is enforced indirectly, through ethics-committee approval requirements, sponsor SOPs, and journal publication policies, rather than through any WMA enforcement mechanism.
References
- World Medical Association, “WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants” (current text, revised by the 75th WMA General Assembly, Helsinki, October 2024), wma.net/policies-post/wma-declaration-of-helsinki/ — primary source for all paragraph citations above, directly verified 2026-08-16.
- World Medical Association, WMA DoH 1964–2024 archive (prior revision texts back to 1964), wma.net.
- International Council for Harmonisation, ICH Harmonised Guideline: Good Clinical Practice E6(R2)/E6(R3).
- See also CASRAI’s entries on the Declaration of Helsinki, Nuremberg Code, and Belmont Report for the surrounding lineage of research-ethics codes, and the HIPAA authorization vs. informed consent comparison for how U.S. privacy law interacts with consent obligations.
